-
Researchers continue to investigate cardioprotective effects of GLP-1 receptor agonists
Glucagon-like peptide-1 (GLP-1) receptor agonists reduce the risk of myocardial infarction, stroke, and similar cardiovascular events, but questions remain about the mechanisms behind the cardioprotection the drugs provide. During a Virtual Scientific Sessions symposium, Daniel J. Drucker, MD, and two other researchers will address the question, How Do GLP-1 Receptor Agonists Provide Cardioprotection?
-
With limited health care dollars, do the benefits of CGM justify the additional costs in type 2 diabetes care?
During a virtual presentation at the Scientific Sessions, Athena Philis-Tsimikas, MD, and Elbert Huang, MD, MPH, FACP, will debate the value of continuous glucose monitoring (CGM) in patients with type 2 diabetes. ADAMeetingNews.org spoke to Drs. Philis-Tsimikas and Huang for a preview of the debate.
-
Expert panel to provide update on lipid-lowering drugs
Four experts will provide an update on lipid-lowering drugs during a two-hour virtual presentation at the Scientific Sessions. The session’s panelists include Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC; Jennifer G. Robinson, MD, MPH; and John R. Guyton, MD.
-
Scientific Sessions include four days of virtual networking opportunities for ADA members
ADA’s Interest Group Leadership Teams have been hard at work planning virtual networking events, which will allow members to linger virtually at the back of the lecture hall discussing new research, share perspectives on a variety of hot topics in diabetes, and contribute to the future planning of ADA’s Interest Group activities.
-
Investigators will review latest data from VERTIS-CV trial of SGLT2 inhibitor ertugliflozin
Detailed findings from the VERTIS-CV trial looking at the safety and efficacy of ertugliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, will be presented Tuesday, June 16, by a panel of trial investigators. Christopher P. Cannon, MD, a member of the VERTIS-CV trial Scientific Advisory Committee, will present cardiovascular and renal outcomes from the trial.
-
TEDDY Study providing insight into the type 1 diabetes disease process in children
A panel of investigators, including Beena Akolkar, PhD, will present recent findings from the ongoing TEDDY Study during the Scientific Sessions. TEDDY is a multi-center study funded by the NIDDK designed to investigate the etiology of type 1 diabetes and identify environmental triggers of the disease.
-
Joint symposium to examine role of time-in-range in pediatric diabetes
Ongoing advances in the accuracy and affordability of continuous glucose monitoring technologies have led to a growing emphasis on time-in-range as a primary metric in pediatric diabetes. A panel of experts, including Daniel J. DeSalvo, MD, will review the growing evidence supporting time-in-range and discuss recommendations for incorporating the metric into clinical practice during the…
-
With very few exceptions, Virtual 80th Scientific Sessions will feature entire program planned before COVID-19
On Friday, April 3, the global COVID-19 (coronavirus) pandemic forced the ADA to restructure its flagship professional event from an in-person meeting to a virtual experience to be held over the same dates, June 12-16, 2020. What won’t change, according to Jose C. Florez, MD, PhD, Chair of the 80th Scientific Sessions Meeting Planning Committee,…
-
Panel to explore treatment options tailored to diabetes comorbidities
During a Friday afternoon symposium at the Scientific Sessions, a panel of experts will discuss the latest recommendations and research findings regarding treatment options for patients with common diabetes comorbidities. Panelists include George Bakris, MD, Silvio E. Inzucchi, MD, and Jesse Dawson, MD, BSc (Hons), FRCP, FESO.
-
PIONEER 6 results show reduced MACE with oral semaglutide in type 2 diabetes patients with high CV risk
Results from the PIONEER 6 trial suggest that oral semaglutide is safe for patients with type 2 diabetes at high cardiovascular (CV) risk. PIONEER researchers, including Mansoor Husain, MD, and John B. Buse, MD, PhD, reported that oral semaglutide, the first GLP-1 receptor agonist for oral administration, reduced CV death and all-cause mortality by nearly…